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Abstract: The clinical outcome of patients with ischemic heart disease can be significantly 
improved with the implementation of targeted drug delivery into the ischemic myocardium. 
In this paper, we present our original findings relevant to the problem of therapeutic heart 
targeting with use of nanoparticles. Experimental approaches included fabrication of carbon and 
silica nanoparticles, their characterization and surface modification. The acute hemodynamic 
effects of nanoparticle formulation as well as nanoparticle biodistribution were studied in male 
Wistar rats. Carbon and silica nanoparticles are nontoxic materials that can be used as carriers 
for heart-targeted drug delivery. Concepts of passive and active targeting can be applied to the 
development of targeted drug delivery to the ischemic myocardial cells. Provided that ischemic 
heart-targeted drug delivery can be proved to be safe and efficient, the results of this research 
may contribute to the development of new technologies in the pharmaceutical industry.
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Introduction
The concept of targeted drug delivery (TDD) implies selective accumulation of a 
drug within the affected tissue after systemic administration of the carrier-bound drug 
with the minimal possible side effects on irrelevant organs and tissues.1 The idea of 
TDD was first introduced by Paul Erlich in 1906, who put forward the concept of the 
“magic bullet” directed against the target cell alone, with no damage to healthy cells.2 
Site-targeted nanosized particles as drug carriers may offer an advantage of safety and 
efficacy superior to that of more routine prototypes.
A typical nanoparticulate carrier for TDD includes several functional elements. Its 
major part is the drug-loaded nanoparticle. An important step in its fabrication is the 
functionalization of the particle, which implies the binding of the targeting ligand to 
the particle surface. The ligand should ensure specific interaction of the particle with 
the complementary molecule, whenever delivered to the target cell. The nanoparticles 
can also be bound to radioactive isotopes or fluorescent dyes, which allow their visu-
alization in the tissue of interest. Effective TDD with use of nanoparticulate carriers 
can bring solutions to such problems as drug toxicity, insufficient bioavailability, poor 
solubility and stability.
To date, the research on TDD has been mostly concentrated on the development of 
tumor-targeted nanomedicines. It might be hypothesized that TDD strategy approved International Journal of Nanomedicine 2010:5 232
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in oncology can be applied in other clinical fields, not for 
destruction of specific tissue, more for the salvage of revers-
ibly injured cells; – in particular cells destined to die within 
the area of myocardial ischemia-reperfusion. One reasonable 
approach to the problem may be targeted intramyocardial 
delivery of the agents (such as certain angiogenic growth 
factors, erythropoietin, adenosive triphosphate (ATP) -sen-
sitive potassium channel openers), either covalently and/or 
noncovalently bound to the nanoparticulate carriers. One may 
suppose that local accumulation of drug-loaded nanoparticles 
within the ischemic area of the heart can at least in principle 
be achieved by selective binding of annexin V to the particle 
surface. Annexin V is a naturally expressed soluble protein 
that binds to phosphatidylserine head in a calcium-dependent 
fashion. Phosphatidylserine is normally localized to the inner 
surface of the plasma membrane, but when sublethal cell 
injury occurs it is translocated to the external layer the cell 
surface.3 Annexin V is widely used as a marker protein for 
the visualization of cell injury and apoptotic death in vitro. 
Specific interaction of the nanoparticle-anchored annexin V 
with phosphatidylserine would potentially ensue the binding 
of nanoparticles to the cardiomyocyte membrane with their 
subsequent accumulation in the area of interest.
Apart from the active heart targeting by annexin V, we 
cannot rule out the probability that passive targeting may be 
helpful in treating ischemic-reperfused myocardium.4 The 
basic idea is that the nanoparticulate carriers can be retained 
and accumulated within the ischemic-reperfused area of the 
heart owing to increased microvascular permeability to all 
macromolecules, the nanocarrier including.5 In this regard, 
the functional characteristics of myocardial microvessels 
are more or less similar to those of the tumor, which would 
make the proposed approach even closer to that already 
practiced.
In this study, we provide preliminary evidence that 10 nm 
silica nanoparticles (SNP) might be used for heart-targeted 
drug delivery in both passive and active ways as described 
above. The study was aimed at the development of a tech-
nique of SNP functionalization, evaluation of SNP effects on 
the parameters of systemic hemodynamics, and investigation 
of SNP biodistribution using optical fluorescence.
Materials and methods
Preparation and characterization of sNP
The standard pyrogenic highly dispersed silica (Aerosil® 
of A170, A300, and A380 marks obtained from Vekton™, 
St Petersburg, Russia) was used throughout the experi-
ments. The surface area of SNP was determined using the 
Brunauer–Emmett–Teller (BET) method and averaged 
from 170 to 380 m2/g. The mean particle diameter varied 
from 6 to 13 nm. The technique of SNP functionalization 
included three sequential steps: modification of SNP with 
(3-aminopropyl)triethoxysilane, hydrolysis of unreacted 
alkoxysilane groups, and binding of fluorescein. Chemosorp-
tion of (3-aminopropyl)triethoxysilane was performed from 
the gaseous phase with use of dried nitrogen as a carrier gas. 
The synthesis was done in the vertical quartz flow reactor at 
220°C for 2 hours. Hydrolysis of the unreacted alkoxysilane 
groups was achieved with water vapor at 150°C for 1 hour. 
The covalent binding of fluorescein to the aminated silica 
was done using carbodiimide technique for 1 hour (Scheme 1 
and 2). All chemicals were purchased from Sigma-Aldrich 
Chemical Co (Moscow, Russia). The surface reactions were 
controlled with infrared spectroscopy (diffuse reflection) 
(Perkin–Elmer 1760×). The amount of fluorescein bound to 
the surface of SNP was determined spectrophotometrically at 
λ = 490 nm. Fluorescein content within the samples of modi-
fied SNP varied from 0.01 to 0.02 mM/g. Another fluorescent 
dye that can be used for labeling of SNP is considered to be 
indocyanine green (ICG). This fluorophore has an absorp-
tion band in the near-infrared region (λ = 780 nm). We have 
developed the technique of indocyanine green immobiliza-
tion on the surface of aminated silica. First of all, it has been 
established that the sample obtained is stable in the saline 
to be used for the evaluation of nanoparticle biodistribution. 
Then, fluorescently labeled SNP were used for biodistribution 
studies (see below).
Acute toxicity and biodistribution
We studied in the rat model the acute effect of nanoparticle 
formulations on basic hemodynamic parameters. For this 
purpose, the suspensions of silica (nSiO2), fluorescein-doped 
silica (nSiO2 + fluorescein), and carbon (nC) nanoparticles 
in 0.9% sodium hydrochloride solution were prepared. In all 
suspensions, the final concentration of either silica or carbon 
was 2 mg/mL. The binding of fluorescein to the nanoparticle 
surface was performed using the chemical assembly method 
described above. Fluorescein concentration in the suspension 
of nSiO2 + fluorescein was about 0.013 mg/mL.
Male Wistar rats, 250 to 300 g body weight were used 
throughout the experiments. The animals were fed regular 
chow, and water was available ad libitum. All experiments 
were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (publication No. [NIH] 
85-23). The animals were anesthetized with sodium pen-
tobarbital (60 mg/kg). The trachea was intubated through International Journal of Nanomedicine 2010:5 233
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a cervical incision. In spontaneously breathing animals the 
right carotid artery and femoral vein were cannulated for 
blood pressure monitoring and anesthesia maintenance, 
respectively. The other femoral vein was cannulated for 
infusion of the solutions to be tested. Measurements of heart 
rate (HR), mean arterial pressure (MAP) and pulse arterial 
pressure (PAP) were done in all groups at baseline, that is, 
2 minutes before the first infusion. The volume of the first 
infusion for any tested nanoparticle formulation was 0.2 mL, 
while for two following infusions it was 0.4 mL, so that the 
total volume was 1 mL (0.7 mg of nanoparticulate carrier per 
100 g of the animal body weight). The intravenous infusions 
of the equivalent amounts of 0.9% sodium hydrochloride 
were performed in the controls. In all groups, the infusions 
were separated by a 20 minute rest period. The hemodynamic 
responses to infusions were evaluated at the next time points: 
2 minutes after initiation of each infusion, by the end of each 
infusion, as well as 10 minutes and 20 minutes following 
each infusion (Figure 1).
The biodistribution of SNP was determined by fluores-
cence imaging. Fluorescein and indocyanine green were used 
for labeling of SNP. The animals (n = 3 for each fluorescent 
dye) received intravenous infusion of fluorescently labeled 
nanoparticles suspended in normal saline at a volume of 
1 mL totally for 10 minutes. Twenty minutes after the end of 
each infusion, the animals were sacrificed by an overdose of 
anesthesia, and heart, brain, liver, spleen, lung, and kidney 
were removed for subsequent measurements. Control animals 
(n = 3) were treated with the vehicle alone. The fluores-
cence was registered using the home-made FLUM3 setup 
equipped with mercury lamp illuminator and TV camera. The 
fluorescence of fluorescein- and indocyanine green-labeled 
nanoparticles was elicited using band-pass interference filters 
of 435 and 780 nm, respectively. The images obtained in the 
experiments with fluorescein-labeled nanoparticles were split 
into red, green, blue (RGB) channels. Channel G has been 
chosen as a target one. The relative change in the fluorescence 
intensity (percentage change as related to the control, ∆G%) 
has been calculated as follows: ∆G = (G2–G1)/G1, where 
G1 is the level of (auto)fluorescence in controls, G2 – the 
fluorescence intensity of samples obtained from the animals 
treated with nSiO2 + fluorescein. In the experiments with 
indocyanine green-labeled nanoparticles, black-and-white 
images were obtained, and the relative change in the fluores-
cence level (ie, percentage change from control, ∆F%) was 
calculated as described above. Measurement of fluorescence 
intensity was performed with use of Ecoskin software 1.0.1. 
Statistical analysis was performed by the Mann-Whitney 
U test, with P values 0.05 considered significant.
Results
Acute effects of nanoparticle suspensions 
on hemodynamic parameters
Hemodynamic data are summarized in Table 1. Briefly, in all 
animal groups, there were no significant alterations in heart 
rate throughout the trials. The first infusion of any nanopar-
ticle formulation tested had no effect on hemodynamic 
parameters (see also Figure 2). Furthermore, there was no 
significant difference in MAP between the baseline time point 
and the end of the experiment. However, both second and 
third infusions of nSiO2 evoked transient increase of MAP 
(Figure 2). Infusions of nC or saline alone did not affect the 
MAP values assayed. There was a significant increase in PAP 
of the animals that received nSiO2 or nC at the end of the 
observation. Administration of nSiO2 + fluorescein resulted in 
an increase of PAP too, while PAP in the controls remained 
unaffected throughout the experiment (Table 1).
Thus, intravenous infusion of distinct nanoparticle for-
mulations caused mild changes in systemic hemodynamics 
which appears to be indicative of the appropriate biocompat-
ibility of nanomaterials tested.
Biodistribution
The biodistribution data are shown in Table 2. It should be noted 
that exposure of the organ samples to UV light (λ = 435 nm) for 
detection of fluorescein-doped nanoparticles was associated 
0.2 mL
30 min 20 min 20 min 20 min
0.4 mL 0.4 mL
Figure 1 experimental protocol. ↓ – time point of evaluation of hemodynamic parameters.International Journal of Nanomedicine 2010:5 235
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with significant autofluorescence that may interfere with the 
signal of interest. We nevertheless were able to discriminate 
statistically between meaningful and background signals to 
show the predominant accumulation of fluorescein-labeled 
nanoparticles within the lung, spleen and liver, that is, in the 
organs of RES. Besides, indocyanine green has proved to 
be helpful for the avoidance of tissue excessive autofluores-
cence at λ = 780 nm. Concerning indocyanine green-labeled 
nanoparticles, the highest accumulation was within the liver 
and kidney compared to other organs. Therefore, for fluores-
cent labeling of SNP and investigation of their biodistribution 
the infrared fluorophores appear to be preferable.
Discussion
Although the idea of TDD to the ischemic heart put forward 
in this paper seems to be justified, at least in principle, the 
following problems lie ahead. Since systemic administration 
of drug nanocarriers results in their selective accumulation in 
the targets under conditions of normal blood flow, it remains 
to be solved in what way their effective concentration can be 
achieved in the ischemic hearts. Supposedly, the increased 
residence time of nanocarriers within the normally perfused 
tissue adjacent to ischemic one would be the solution if one 
takes into consideration the sufficient diffusion between the 
two. An alternative solution may be an increase in payloading 
of each nanoparticle with drugs and/or targeting ligands. It 
should be borne in mind, however, that such a strategy might 
be at substantial risk of the competitive uptake of nanocarriers 
by the immune system at the expense of the targets.
Insufficient evidence is available on the clinical effec-
tiveness of nanoparticulate drug carriers. More studies are 
required to elucidate the pharmacokinetics of nanocarriers, 
their biodistribution and putative toxicity. All of the newly 
developed nanosystems for targeted delivery demonstrate 
unique properties and need careful testing. The refinement 
of the techniques of nanocarrier fabrication is under way and 
aimed primarily at ensuring better uptake of nanoparticles by 
the target cells, formation of a higher gradient of drug concen-
tration between injured and unaffected tissue, and lowering 
drug toxicity. The solution of these problems would be a major 
step in the development of the “ideal tool” for well-addressed 
delivery of the drug into the tissue of interest.
In the current study, it was shown that intravenous infu-
sion of SNP is associated with mild changes in hemodynamic 
parameters. This is indicative of the lack of acute toxicity of the 
nanoparticle formulations tested. An important issue related 
to the potential use of SNP for medical applications is their 
biocompatibility and biodegradability. It has been found before International Journal of Nanomedicine 2010:5 236
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Figure 2 The effect of different nanoparticle formulations on arterial pressure.
Abbreviations: nc, carbon nanoparticles; nsiO2, silica.
in the cell culture experiments that mesoporous SNP did not 
affect cell viability as well as plasma membrane integrity.6 
Furthermore, mesoporous SNP were recently used for glucose-
responsive controlled release of both insulin and cyclic adenos-
ine monophosphate,7 for intracellular delivery of cysteine,8 
hydrophobic fluorophores,9 and genetic constructs.10 It should 
be noted however, that long-term biocompatibility of SNP 
awaits further investigation in the relevant models. As to the 
biodegradability of silica nanomaterials, the first evidence on 
this issue is also encouraging. One recent study suggested that 
Table 2 Distribution of fluorescein (FLU)- and indocyanine green (ICG)-labeled silica nanoparticles in different rat organs 30 minutes 
after nanoparticle administration
Organ λ = 780 nm λ = 435 nm
Control,  
F1a
ICG-labeled  
nanoparticles, F2
∆F% Control,  
G1b
FLU-labeled  
nanoparticles, G2
∆G%
heart 12,5 ± 0,5 22,5 ± 0,5 80,8 ± 3,9 90,2 ± 13,2 106,0 ± 7,0 18,2 ± 9,3
Brain 26,5 ± 0,5 35,5 ± 0,5 77,1 ± 7,0 115,0 ± 7,1 119,5 ± 13,4 5,5 ± 2,8
Liver 14,5 ± 0,5 1213,5 ± 193,0 8311,4 ± 1232,0 94,7 ± 31,5 113,5 ± 24,8 22,3 ± 14,6
spleen 16,0 ± 9,9 20,0 ± 4,2 62,1 ± 27,0 80,7 ± 10,2 99,0 ± 7,1 23,1 ± 6,8
Lung 29,0 ± 5,7 127,5 ± 24,8 356,6 ± 123,0 87,6 ± 6,0 113,5 ± 2,1 30,0 ± 11,4
Kidney 16,0 ± 5,7 164,0 ± 21,2 1018,3 ± 373,0 76,3 ± 0,4 82,2 ± 6,2 9,3 ± 6,7
Notes: aTotal fluorescence intensity. bFluorescence intensity restricted to channel G.
Abbreviations: ∆F, change in fluorescence as a percentage; ∆G, change in green as a percentage.International Journal of Nanomedicine 2010:5
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porous sol–gel silica microparticles can be rapidly eliminated 
from the organism.11 The metabolic pathway for silica bio-
degradation includes erosion of the nanoparticle surface with 
formation of plasma-soluble silicic acid and its subsequent 
excretion by the kidney.
In conclusion, targeted delivery of the nanoparticle-bound 
drugs to the ischemic cardiac muscle seems to be a challenging 
strategy to treatment of coronary artery disease. Our results 
suggest that SNP are not toxic during acute intravenous admin-
istration. Functionalization of SNP can be reliably achieved by 
either immobilization or chemical assembly. Infrared fluoro-
phores such as indocyanine green are preferable for fluorescent 
labeling of SNP and investigation of their biodistribution.
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